Date: 2015-04-17
Type of information: Initiation of the trial
phase: 1-2
Announcement:
Company: Eli Lilly (USA - IN) BMS (USA - NY)
Product: galunisertib and nivolumab
Action
mechanism: monoclonal antibody. Opdivo® (nivolumab) is a fully-human PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T-cells. PD-1, a receptor expressed on the surface of lymphocytes, plays a role in a regulatory pathway that suppresses activated lymphocytes in the body. Available evidence suggests that cancer cells exploit this pathway to escape from immune responses. Opdivo® is thought to provide benefit by blocking PD-1-mediated negative regulation of lymphocytes (i.e., the interaction of PD-1 with its ligands PD-L1 and PD-L2), thereby enhancing the ability of the immune system to recognize cancer cells as foreign and eliminate them. Opdivo® is the world’s first approved drug targeting PD-1. This monoclonal antibody has been generated under a research collaboration entered into in May 2005 between Ono and Medarex. When Medarex was acquired by BMS in 2009, it also granted BMS its rights to develop and commercialize the anti-human PD-1 monoclonal antibody in North America. Through the collaboration agreement entered into in September 2011 between Ono and BMS, Ono granted BMS exclusive rights to develop and commercialize Opdivo® in the rest of the world, except in Japan, Korea and Taiwan where Ono has retained all rights to develop and commercialize the compound. kinase inhibitor. Galunisertib (LY2157299) is a TGF beta R1 kinase inhibitor that in vitro selectively blocks TGF beta signaling. TGF beta promotes tumors growth, suppresses the immune system, and increases the ability of tumors to spread in the body. Immune function is suppressed in cancer patients, and TGF beta worsens immunosuppression by enhancing the activity of immune cells called T regulatory cells. TGF beta also reduces immune proteins, further decreasing immune activity in patients Galunisertib is currently under investigation as an oral treatment for advanced/metastatic malignancies, including Phase 2 evaluation in hepatocellular carcinoma, myelodysplastic syndromes (MDS), glioblastoma, and pancreatic cancer.
Disease: solid tumors, non-small cell lung cancer, hepatocellular carcinoma, glioblastoma
Therapeutic area: Cancer - Oncology
Country: Spain, USA
Trial
details: The main purpose of this study is to evaluate the safety, tolerability, and efficacy of the study drug known as galunisertib in combination with nivolumab in participants with advanced refractory solid tumors and in recurrent or refractory non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC) or glioblastoma. (NCT02423343)
Latest
news: The sutyd is a phase 1b/2 dose escalation and cohort expansion study of the safety, tolerability and efficacy of a novel transforming growth factor-beta receptor I kinase inhibitor (galunisertib) administered in combination with anti-PD-1 (nivolumab) in ddvanced refractory solid tumors (Phase 1b) and in recurrent or refractory non-small cell lung cancer, hepatocellular carcinoma, or glioblastoma (Phase 2). In January 2015, BMS and Eli Lilly announced a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Opdivo® (nivolumab) in combination with galunisertib (LY2157299).
